Down 81% since going public, could this iconic FTSE 250 company be a January bargain?

Oliver Rodzianko takes a look at Dr. Martens from the FTSE 250 to see if this could be an opportune time for him to buy some of its shares.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Caucasian woman with pink her studying from her laptop screen

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in shares that are down over 80% can seem daunting. After all, some companies’ share prices fall for good reason. Yet, I think this FTSE 250 business might be an opportunity.

Most people know Dr. Martens (LSE:DOCS) well. It’s become iconic in London, and the brand has spread around the world for its fashionable footwear.

The company has had rich cultural significance since the 1960s. It also initiated a successful turnaround culminating in 2010. But are the shares really worth me owning today?

Doc Martens in 2024

This year, the management is focusing on driving sustainable profitability and growth, focusing on shareholder value.

It currently has a strategy called DOCS, focused on direct-to-customer sales, operational excellence, customer connections, and supporting business-to-business partnerships.

The company now operates in three primary regions: Europe, Middle East, and Africa (EMEA); the Americas; and Asia Pacific (APAC).

It sells products from various segments, including Originals, Fusion, Kids, and Casual ranges.

A closer look at the financials

The firm has reported growing revenues and earnings since its initial public offering (IPO) in 2021. However, there’s been significant volatility in the results, particularly for its earnings per share:


Source: TradingView

While the above graph paints a turbulent financial picture for Dr. Martens in the last few years, generally the company’s growth is good.

After all, the firm’s three-year average annual revenue growth rate is over 14%.

Also, the company’s price-to-earnings (P/E) ratio stands at around eight, particularly cheap compared to past prices. It’s also strong for its sector, considering an industry median of around 19.


Source: TradingView

While the above points look relatively promising to me, the organisation’s balance sheet does present some cause for concern.

As of its last annual report in March, it had £446m in debt and only £158m in cash on its books.

While that’s not terrible, it has gotten worse, and taking into account the trailing 12-month period, it has £530m in debt and £46m in cash. If the company faces economic hardships, it might need to raise more finances to pay its debts.

Other risks I’m considering

As of 26 January 2024, the Dr. Marten’s share price had dropped 39% in a year. While the company faced a significant drop in revenue during the period, it did maintain its trading expectations.

To me, that means such a steep decline in the share price was slightly unwarranted. However, it outlines a risk of volatility for Dr. Marten’s shareholders.

Also, while inflation and interest rates are expected to ease soon, there’s no guarantee of this, and any wider economic setbacks could contribute to reduced consumer spending over some time. Therefore, I think the shares might have slower or even negative growth in the near future.

It’s on my watchlist

I’m taking my time before adding these value shares to my portfolio.

As I’ve learned from Warren Buffett: I don’t need to pick many great investments in my lifetime to end up rich. It’s the quality of the ones I choose that really matters. Deciding on that often takes time.

If I do invest, I’ll be giving it at least five years to start seeing the investment returns I’d like. That’s not something I mind, as I like to buy investments with the intention of holding them for at least a decade.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Oliver Rodzianko has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Can Rolls-Royce shares keep on soaring in 2025?

2024 so far has been another blockbuster year for Rolls-Royce shares. Our writer thinks the share could still move higher.…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

Here’s the worst thing to do in a stock market crash (it isn’t selling)

When the stock market falls sharply – as it does from time to time – selling is often a bad…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

My top 2 growth shares to consider buying in 2025

For investors looking for top growth shares to buy in the New Year, I reckon this pair are well worth…

Read more »

Investing Articles

3 massive UK shares that could relocate their listing in 2025

I've identified three UK companies that may consider moving their share listing abroad next year. What does this mean for…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

2 common mistakes investors make with dividend shares

Stephen Wright outlines two common mistakes to avoid when considering dividend shares. One is about building wealth, the other is…

Read more »

Investing Articles

Here’s how I’ll learn from Warren Buffett to try to boost my 2025 investment returns

Thinking about Warren Buffett helps reassure me about my long-term investing approach. But I definitely need to learn some more.

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Here are the best (and worst) S&P 500 sectors of 2024

While the S&P 500 has done well as a whole, some sectors have fared better than others. Stephen Wright is…

Read more »

Investing Articles

2 FTSE 100 stocks I think could be takeover targets in 2025

If the UK stock market gets moving in 2025, I wonder if the FTSE 100 might offer a few tasty…

Read more »